Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
Go back to Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia| BIO-PATH HOLDINGS (NASDAQ: BPTH) | Delayed: 2.64 +0.01 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.63 | 52 Week High | $3.19 | |||
| Open | $2.64 | 52 Week Low | $0.95 | |||
| Day High | $2.64 | P/E | N/A | |||
| Day Low | $2.64 | EPS | $0.00 | |||
| Volume | 226 | |||||
